Quantum BioPharma
@QuantumBP
Innovating in Neurodegenerative Disease & Alcohol Health. Creators of unbuzzd™️ & Lucid-MS. Strong Execution. Diversified Treasury. NASDAQ symbol $QNTM
Our Partners at @getunbuzzd🍋
Big Papi David Ortiz Showing Some Love for unbuzzd!!! ⚾️🏟️🍻💚💛 We Love You Big Papi!!!!! #unbuzzd #unbuzzdwellness #ownnowandwhatsnext #hangover #hangoverrelief #preventhangover #prevention #greattasting #citrus #hydrate #hydration #BigPapi #DavidOrtiz #BigPapiDavidOrtiz…
Quantum BioPharma Makes Strategic Investment in GameStop Corp. $GME $QNTM globenewswire.com/news-release/2… #Gamestop #GME #Gaming #Games #NASDAQ
Podcast with @KnotLegaladvice CEO Zeeshan Saeed @zsaeed , Kevin Malone @Malone_Wealth & Jason Sawyer $QNTM #Nasdaq
ceo Zeeshan Saeed & Quantum x.com/i/broadcasts/1…
🧠 Disrupted neural communication is a key challenge in Multiple Sclerosis. Lucid-MS, Quantum BioPharma’s investigational therapy, is designed to target demyelination—a core driver of this disruption. We’re advancing science with a clear focus: restoring the pathways that…
#BurgersToBeatMS is back! 🍔 On August 21, $2 from every @awcanada Teen Burger® sold across the country will support Canadians affected by #MS. Canada has one of the highest rates of MS in the world. Your support truly matters! Learn more: bit.ly/3ICmRR8
$QNTM
New Pain Treatment Approved for Testing @QuantumBP NASDAQ: QNTM / CSE: QNTM ✅ Australia has approved new study for FSD202 — a treatment for hard-to-treat pain in people with MCAS 👥 60 people will take part in the study across several hospitals 💡 MCAS is a condition where…
Stories like this are exactly why we’re driven at Quantum BioPharma. They remind us what’s at stake and inspire our team to keep advancing the science. Our mission is clear: to bring hope and real progress to those living with MS. Thank you for sharing your strength and your…
If you had the chance to tell MS anything, what would you say? #MSAwarenessWeek #MSEndsWithUs
$QNTM
FDA Submission in Progress for Lucid‑MS Phase 2 Trial @QuantumBP NASDAQ: QNTM / CSE: QNTM 💡 Lead therapy Lucid‑MS successfully completed Phase 1 trials — no serious side effects reported ✅ FDA submission now in preparation for Phase 2 clinical trial approval 🧠 Targets…
3rd Party Article @MSNewsToday multiplesclerosisnewstoday.com/news-posts/202… #Multiplesclerosis #MS #Biotech #Nasdaq $QNTM #Neurodegenerative
🔬 Advancing the Science of Demyelination. Dedicated to Addressing the Complexities of Neurodegenerative Disease. Quantum BioPharma Operates with Scientific Integrity at Every Step. Learn more at: 🌐 quantumbiopharma.com #Biotech #MultipleSclerosis #Demyelination $QNTM…
$QNTM
A Major Step Forward in MS Treatment @QuantumBP NASDAQ: QNTM / CSE: QNTM 🧠 90-day safety study for Lucid-MS completed — no issues reported 📄 FDA application in progress with global research partner 🌍 Submitted to UK fast-track program for accelerated review Multiple…
$QNTM
Quantum BioPharma Seeks Fast-Track Review in the UK for New MS Treatment @QuantumBP NASDAQ: QNTM / CSE: QNTM ✅ Lucid-MS submitted to UK program to speed up review ✅ A patented new drug designed to help people with Multiple Sclerosis ✅ Completed Phase 1 safety trial — on…
Quantum BioPharma has submitted its patented MS drug candidate, Lucid-21-302 (Lucid-MS), to the UK’s Innovative Licensing and Access Pathway (ILAP) fast-track program. Lucid-MS is a first-in-class treatment targeting demyelination in Multiple Sclerosis. The ILAP submission…
NEWS RECAP JUNE 17th 2025 Quantum BioPharma ($QNTM) and Massachusetts General Hospital (MGH) have officially scanned the first person with Multiple Sclerosis using a next-generation PET-MR imaging tracer—[¹⁸F]3F4AP, Using latest tech GE Signa PET-MR. This groundbreaking joint…
🇺🇸 Happy 4th of July from all of us at Quantum BioPharma! 🇺🇸
$QNTM
MS Treatment Market Projected to Reach $46.4 Billion by 2033 @QuantumBP NASDAQ: QNTM / CSE: QNTM 🧠 Most current treatments only manage symptoms — leaving a need for options that protect and heal the brain. Lucid-MS is being developed to help repair the myelin layer that MS…